BEHAVIOURAL SCIENCE IN CANCER SCREENING, CONTROL AND COMMUNICATION
With
Dr Rachael Dodd
Senior Research Fellow,
The Daffodil Centre, a Cancer Council NSW & The University of Sydney Joint Venture
Sydney, Australia
RESEARCHER PROFILE
Filmed in Sydney | April 2025
Dr Dodd completed her undergraduate in Psychology (2007), Masters in Health Psychology (2009) and PhD in Psychology (2016) in the UK. Her PhD focused on the psychosocial impact of HPV in people diagnosed with head and neck cancer, which resulted in the development of an education resource which is being implemented into clinical practice here in Australia and is available online. Dr Dodd relocated to The University of Sydney in Australia in 2017, following the completion of her PhD. Her research capitalised on her expertise in HPV and focused on the changes to the cervical screening program that commenced in Australia in 2017.
Dr Dodd has an established international reputation as a behavioural scientist in cancer control and communication. Since completing her PhD in 2016, Dr Dodd has been awarded a three-year University of Sydney Postdoctoral Research Fellowship (2018-2021) and a three-year Research Fellowship at The Daffodil Centre (current). Dr Dodd is the co-chair of the ‘Strengthening and optimising approaches to cancer prevention, screening, and early detection’ hub at The Daffodil Centre (with more than 130 staff and students).
Dr Dodd has published 78 research papers and is a CI on grants worth over $20 million. This has included being the lead investigator of an International Lung Cancer Foundation Young Investigator Grant, to co-design decision support tools for lung cancer screening in Australia and she is leading a consortium to develop the suite of information materials and education resources for the upcoming National Lung Cancer Screening Program.
Source: Supplied
https://orcid.org/0000-0002-8080-6359
-
Dr Paul Griffin
MATER HEALTH SERVICES, QUEENSLAND, AUSTRALIA
-
Superslayer taking on antibiotic-resistant bacteria
Dr Katharina Richter is a visionary leader in MedTech, acclaimed for innovation and gender diversity. With over 40 awards to her name, including MIT Innovator Under 35 Asia-Pacific, and Prime Minister’s Prize for New Innovator finalist, she has shattered barriers as an entrepreneur, scientist, and ‘superbug slayer.’ Katharina’s groundbreaking work in combating antibiotic-resistant bacteria has resulted in 6 innovative treatments, 3 of which are patented, offering hope against deadly infections.
-
Exercise therapy for metabolic dysfunction-associated steatotic liver disease
Dr Shelley Keating is a Senior Lecturer in Clinical Exercise Physiology and Accredited Exercise Physiologist from the School of Human Movement and Nutrition Sciences at the University of Queensland. With a strong grounding in exercise metabolism and body composition, Dr Keating’s research centres on the utility of exercise as a therapy for obesity and related cardiometabolic conditions, notably metabolic dysfunction-associated steatotic liver disease (MASLD).
